Design of innovated lipid-based floating beads loaded with an antispasmodic drug: in-vitro and in-vivo evaluation

被引:24
作者
Adel, Sally [1 ]
ElKasabgy, Nermeen Adel [1 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo 11562, Egypt
关键词
Drotaverine hydrochloride; glass transition temperature; isopropylmyristate; pharmacokinetics; CONTROLLED-RELEASE PHARMACEUTICALS; FREE-BOUNDARY PROBLEMS; MECHANICAL-PROPERTIES; GEL BEADS; MICROSPHERES; PLASTICIZERS; FORMULATION; DIFFUSION; SYSTEM;
D O I
10.3109/08982104.2013.857355
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Context: Drotaverine hydrochloride (DRT) is used to treat gastrointestinal spasms accompanied with diarrhoea. Hence, the drug suffers from brief residence in the highly moving intestine during diarrhoea which leads to poor bioavailability and frequent dosing. Objective: This study aimed to extend DRT residence in the stomach. Methods: Calcium alginate floating beads were prepared using sodium alginate, isopropylmyristate (oil), and Gelucire (R) 43/01 (lipid) adopting emulsion gelation technique. The beads were evaluated for their floating ability, DRT entrapment efficiency and in-vitro release. Gelucire (R) 43/01 /oil-based beads of the selected formula were coated using ethylcellulose and different plasticizers as polyethylene glycol 400 and triethyl citrate to retard the drug release. The coated beads were re-characterized. Finally, the best formulae were investigated for their in-vivo floating ability in dogs besides their delivery to the systemic circulation compared to drug powder in human volunteers. Results: Incorporation of Gelucire (R) 43/01 to oil-based beads enhanced the in-vitro performance of the beads. Coated beads prepared using drug:sodium alginate ratio of 1:3 (w/w), 20% (w/v) isopropylmyristate, 20% (w/v) Gelucire (R) 43/01 showed promising in-vitro performance. The beads floated for 12 h in the dogs' stomach and produced three-fold increase of the total amount of DRT absorbed within 24 h compared to that of DRT powder. Conclusions: Gelucire (R) 43/01 /isopropylmyristate-based calcium alginate floating beads coated with ethylcellulose using either PEG 400 or TEC as plasticizers proved to be a successful dosage form in extending DRT release.
引用
收藏
页码:136 / 149
页数:14
相关论文
共 38 条
[1]   Preparation, characterization and preliminary calcium release study of floating sodium alginate/dextran-based hydrogel beads: part I [J].
Bajpai, Sunil Kumar ;
Tankhiwale, Rasika .
POLYMER INTERNATIONAL, 2008, 57 (01) :57-65
[2]   Design and release characteristics of sustained release tablet containing metformin HCl [J].
Basak, Subal Chandra ;
Kumar, Kesevan Senthil ;
Ramalingam, Murugesan .
REVISTA BRASILEIRA DE CIENCIAS FARMACEUTICAS, 2008, 44 (03) :477-483
[3]   MECHANICAL-PROPERTIES OF DRY AND WET CELLULOSIC AND ACRYLIC FILMS PREPARED FROM AQUEOUS COLLOIDAL POLYMER DISPERSIONS USED IN THE COATING OF SOLID DOSAGE FORMS [J].
BODMEIER, R ;
PAERATAKUL, O .
PHARMACEUTICAL RESEARCH, 1994, 11 (06) :882-888
[4]   Effects of aldehydes and methods of cross-linking on properties of calcium alginate microspheres prepared by emulsification [J].
Chan, LW ;
Heng, PWS .
BIOMATERIALS, 2002, 23 (05) :1319-1326
[5]  
Chauhan Bhaskar, 2004, Acta Pharmaceutica (Zagreb), V54, P205
[6]   Preparation and evaluation of floating risedronate sodium-Gelucire® 43/01 formulations [J].
Chauhan, H ;
Shimpi, S ;
Mahadik, KR ;
Paradkar, A .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (09) :851-860
[7]  
Chien YW., 1990, ENCY PHARM TECHNOLOG
[8]   FREE-BOUNDARY PROBLEMS IN CONTROLLED RELEASE PHARMACEUTICALS .2. SWELLING-CONTROLLED RELEASE [J].
COHEN, DS ;
ERNEUX, T .
SIAM JOURNAL ON APPLIED MATHEMATICS, 1988, 48 (06) :1466-1474
[9]   FREE-BOUNDARY PROBLEMS IN CONTROLLED RELEASE PHARMACEUTICALS .1. DIFFUSION IN GLASSY-POLYMERS [J].
COHEN, DS ;
ERNEUX, T .
SIAM JOURNAL ON APPLIED MATHEMATICS, 1988, 48 (06) :1451-1465
[10]   DIFFUSION IN HPMC GELS .2. PREDICTION OF DRUG-RELEASE RATES FROM HYDROPHILIC MATRIX EXTENDED-RELEASE DOSAGE FORMS [J].
GAO, P ;
NIXON, PR ;
SKOUG, JW .
PHARMACEUTICAL RESEARCH, 1995, 12 (07) :965-971